Skip to main
WVE

WVE Stock Forecast & Price Target

WVE Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 46%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

WAVE Life Sciences is a clinical-stage biotechnology company that has developed a novel platform for creating RNA medicines. This platform allows for the development of therapies for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease. Recent data from a clinical trial showed that the company's leading RNA editing candidate, WVE-006, had lower than desired levels of AAT protein, raising concerns about its commercial competitiveness and regulatory path. Additionally, other competitors have a potential first-mover advantage in the rare disease market. However, the company's strong development pipeline and potential partnerships for commercialization present upside potential for investors.

Bears say

WAVE Life Sciences is facing a number of challenges that could negatively impact its financial performance and stock value. These include delays in its pipeline, particularly the Phase 2a MAD trial and NDA filing for WVE-N53, as well as the lack of a strategic partner for its Huntington's Disease program. Additionally, while WVE-007 has shown promising results for visceral fat loss, the company's focus on ALK7 signaling may be limiting its potential for broader indications and partnerships. These issues, combined with the recent negative reaction to the INLIGHT interim data and uncertainties surrounding the underlying biology, suggest a cautionary outlook for WAVE Life Sciences and its stock.

WVE has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 46% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Wave Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Wave Life Sciences Inc (WVE) Forecast

Analysts have given WVE a Buy based on their latest research and market trends.

According to 13 analysts, WVE has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Wave Life Sciences Inc (WVE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.